Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Staphylococcus aureus resistance poses nonnegligible threats to the livestock industry. In light of this, carbazole-oxadiazoles were designed and synthesized for treating S. aureus infection. Bioassay discovered that 3,6-dibromocarbazole derivative 13a had effective inhibitory activities to several Gram-positive bacteria, in particular to S. aureus, S. aureus ATCC 29213, MRSA and S. aureus ATCC 25923 (MICs = 0.6-4.6 nmol/mL), which was more active than norfloxacin (MICs = 6-40 nmol/mL). Subsequent studies showed that 3,6-dibromocarbazole derivative 13a acted rapidly on S. aureus ATCC 29213 and possessed no obvious tendency to induce bacterial resistance. Further evaluations indicated that 3,6-dibromocarbazole derivative 13a showed strong abilities to disrupt bacterial biofilm and interfere with DNA, which might be the power sources of antibacterial performances. Moreover, 3,6-dibromocarbazole derivative 13a also exhibited slight cell lethality toward Hek 293 T and LO2 cells and low hemolytic toxicity to red blood cells. The above results implied that the active molecule 13a could be studied in the future development of agricultural available antibiotics. Copyright © 2021 Elsevier Inc. All rights reserved.

Citation

Yun-Peng Xie, Mohammad Fawad Ansari, Shao-Lin Zhang, Cheng-He Zhou. Novel carbazole-oxadiazoles as potential Staphylococcus aureus germicides. Pesticide biochemistry and physiology. 2021 Jun;175:104849

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33993967

View Full Text